Shenzhen Bioscien Pharmaceutical

Shenzhen Bioscien Pharmaceutical is a clinical-stage biotechnology company headquartered in Shenzhen, China, dedicated to the development of next-generation cell and gene therapies. The company leverages its proprietary nano-antibody screening and high-titer viral vector platforms to create a robust pipeline of CAR-T cell therapies. Its lead program, PRG-1801, is a BCMA-targeted CAR-T therapy currently being evaluated in Phase 2 clinical trials for the treatment of relapsed or refractory multiple myeloma. Bioscien has entered into significant strategic collaborations, including a major licensing agreement with Huadong Medicine for the commercialization of its lead assets in mainland China. The company's research also extends into dual-target CAR-T therapies and treatments for autoimmune disorders.